Imsidolimab vs spesolimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-36 receptor · full Psoriasis pipeline
Imsidolimab
Developed by Vanda Pharmaceuticals under a licence from AnaptysBio
NCT05352893 · Phase 3 · completed
GEMINI-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 45 patients with a generalized pustular psoriasis flare, randomized 1:1:1 to a single IV dose of imsidolimab 750 mg, 300 mg or placebo. The primary endpoint was GPPPGA 0 or 1 (clear or almost clear) at week 4: 53.3% with 750 mg vs 13.3% with placebo (p=0.0131), so the primary was met. The 300 mg arm had the same response count (8 of 15) on CT.gov, but the release gives no test for it. Sources: CT.gov posted results and the AnaptysBio press release filed on SEC Form 8-K.
Reported efficacy
Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear) (Week 4): GPPPGA 0/1 at week 4: imsidolimab 750 mg IV 53.3% (8/15) vs placebo 13.3% (2/15), p=0.0131; 300 mg IV 8/15 (CT.gov, no test posted for 300 mg) (AnaptysBio release, 9 Oct 2023, SEC 8-K). (met)
Result source: NCT05352893
spesolimab · Spevigo
Marketed by Boehringer Ingelheim and partners
NCT03782792 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled trial that enrolled 53 patients against a planned 51, based on a sample-size calculation in the posted protocol. Its primary endpoint, complete clearance of pustules on the physician global assessment at Week 1, was met with a large difference over placebo (risk difference 48.7 percentage points, one-sided p=0.0004).
Next expected readout: September 2027 · NCT03886246 (registry estimate)
Reported efficacy
Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Spesolimab 900 mg i.v SD 54.3% (95% CI 38.2% to 69.5%) vs Placebo 5.6% (95% CI 1% to 25.8%) (met)
Result source: NCT03782792
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Imsidolimab | spesolimab |
|---|---|---|
| PASI 75 | —Not reported | —Not reported |
| PASI 90 | —Not reported | —Not reported |
| PASI 100 | —Not reported | —Not reported |
| sPGA 0/1 | —Not reported | —Not reported |
| DLQI, change | —Not reported | —Not reported |
PASI 75
- Imsidolimab
- —Not reported
- spesolimab
- —Not reported
PASI 90
- Imsidolimab
- —Not reported
- spesolimab
- —Not reported
PASI 100
- Imsidolimab
- —Not reported
- spesolimab
- —Not reported
sPGA 0/1
- Imsidolimab
- —Not reported
- spesolimab
- —Not reported
DLQI, change
- Imsidolimab
- —Not reported
- spesolimab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Imsidolimab: registry results are on file for Psoriasis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Imsidolimab: 0 of 4 rows · spesolimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | spesolimab |
|---|---|
| Dropout rate | —900 mg i.v.a NCT03782792 · Phase 2 show 15 more results—900 mg i.v. NCT03782792 · Phase 2 8.6%900 mg i.v. SD NCT03782792 · Phase 2 —900 mg i.v. SD NCT03782792 · Phase 2 —Spesolimab IV DD NCT04399837 · Phase 2 —Spesolimab IV SD NCT04399837 · Phase 2 —Spesolimab OL SC NCT04399837 · Phase 2 13.3%Spesolimab SC High Dose NCT04399837 · Phase 2 12.9%Spesolimab SC Low Dose NCT04399837 · Phase 2 9.7%Spesolimab SC Medium Dose NCT04399837 · Phase 2 6.7%double dose NCT05239039 · Phase 3 · registry result, not featured evidence 0%single dose NCT05239039 · Phase 3 · registry result, not featured evidence 0%900 mg i.v. SD NCT05200247 · Phase 3 · registry result, not featured evidence 21.1%BI 655130 High Dose NCT03135548 · Phase 2 · registry result, not featured evidence 26.3%BI 655130 Low Dose NCT03135548 · Phase 2 · registry result, not featured evidence 0% NCT02978690 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —900 mg i.v.a NCT03782792 · Phase 2 show 15 more results—900 mg i.v. NCT03782792 · Phase 2 —900 mg i.v. SD NCT03782792 · Phase 2 —900 mg i.v. SD NCT03782792 · Phase 2 —Spesolimab IV DD NCT04399837 · Phase 2 —Spesolimab IV SD NCT04399837 · Phase 2 —Spesolimab OL SC NCT04399837 · Phase 2 —Spesolimab SC High Dose NCT04399837 · Phase 2 —Spesolimab SC Low Dose NCT04399837 · Phase 2 —Spesolimab SC Medium Dose NCT04399837 · Phase 2 —double dose NCT05239039 · Phase 3 · registry result, not featured evidence —single dose NCT05239039 · Phase 3 · registry result, not featured evidence —900 mg i.v. SD NCT05200247 · Phase 3 · registry result, not featured evidence —BI 655130 High Dose NCT03135548 · Phase 2 · registry result, not featured evidence —BI 655130 Low Dose NCT03135548 · Phase 2 · registry result, not featured evidence — NCT02978690 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 22.2%900 mg i.v.a NCT03782792 · Phase 2 show 15 more results33.3%900 mg i.v. NCT03782792 · Phase 2 —900 mg i.v. SD NCT03782792 · Phase 2 17.1%900 mg i.v. SD NCT03782792 · Phase 2 40%Spesolimab IV DD NCT04399837 · Phase 2 4.5%Spesolimab IV SD NCT04399837 · Phase 2 5%Spesolimab OL SC NCT04399837 · Phase 2 10%Spesolimab SC High Dose NCT04399837 · Phase 2 15.6%Spesolimab SC Low Dose NCT04399837 · Phase 2 3.2%Spesolimab SC Medium Dose NCT04399837 · Phase 2 13.3%double dose NCT05239039 · Phase 3 · registry result, not featured evidence 4.2%single dose NCT05239039 · Phase 3 · registry result, not featured evidence 0%900 mg i.v. SD NCT05200247 · Phase 3 · registry result, not featured evidence 0%BI 655130 High Dose NCT03135548 · Phase 2 · registry result, not featured evidence 5.3%BI 655130 Low Dose NCT03135548 · Phase 2 · registry result, not featured evidence 0% NCT02978690 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 900 mg i.v.a pustular psoriasis 18.5% (placebo 22.2%) diarrhoea 11.1% (placebo 0%) erythema 7.4% (placebo 0%) NCT03782792 · Phase 2 show 14 more results900 mg i.v. pustular psoriasis 33.3% (placebo 22.2%) pyrexia 33.3% (placebo 22.2%) vomiting 33.3% (placebo 5.6%) NCT03782792 · Phase 2 900 mg i.v. SD pustular psoriasis 48.6% (placebo 22.2%) headache 11.4% (placebo 5.6%) nausea 8.6% (placebo 0%) NCT03782792 · Phase 2 asthenia 10% (placebo 0%) chest discomfort 10% (placebo 0%) constipation 10% (placebo 0%) NCT04399837 · Phase 2 pustular psoriasis 22.7% (placebo 53.3%) arthralgia 9.1% (placebo 3.3%) erythema 9.1% (placebo 0%) NCT04399837 · Phase 2 pustular psoriasis 20% (placebo 53.3%) upper respiratory tract infection 20% (placebo 13.3%) urinary tract infection 15% (placebo 0%) NCT04399837 · Phase 2 injection site erythema 16.7% (placebo 3.3%) psoriasis 13.3% (placebo 10%) urinary tract infection 13.3% (placebo 0%) NCT04399837 · Phase 2 pustular psoriasis 28.1% (placebo 53.3%) arthralgia 12.5% (placebo 3.3%) blood creatine phosphokinase increased 12.5% (placebo 6.7%) NCT04399837 · Phase 2 pustular psoriasis 29% (placebo 53.3%) upper respiratory tract infection 19.4% (placebo 13.3%) psoriasis 16.1% (placebo 10%) NCT04399837 · Phase 2 double dose covid-19 40% pyrexia 20% anaemia 6.7% NCT05239039 · Phase 3 · registry result, not featured evidence single dose upper respiratory tract infection 16.7% covid-19 12.5% hyperuricaemia 12.5% NCT05239039 · Phase 3 · registry result, not featured evidence 900 mg i.v. SD pustular psoriasis 18.2% acne 9.1% chest pain 9.1% NCT05200247 · Phase 3 · registry result, not featured evidence nasopharyngitis 42.1% (placebo 38.1%) headache 31.6% (placebo 33.3%) palmoplantar pustulosis 15.8% (placebo 19%) NCT03135548 · Phase 2 · registry result, not featured evidence nasopharyngitis 26.3% (placebo 38.1%) headache 21.1% (placebo 33.3%) arthralgia 15.8% (placebo 4.8%) NCT03135548 · Phase 2 · registry result, not featured evidence arthralgia 42.9% chills 28.6% eczema 28.6% NCT02978690 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
spesolimab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Imsidolimab's landscape · spesolimab's landscape